Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 309

Results For "ARI"

3851 News Found

Study shows Pfizer vaccine moderately effective against Omicron for children 5-15
News | March 12, 2022

Study shows Pfizer vaccine moderately effective against Omicron for children 5-15

The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms


New data show Lynparza demonstrated overall survival benefit in early breast cancer
Biotech | March 12, 2022

New data show Lynparza demonstrated overall survival benefit in early breast cancer

Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial


AbbVie and Gedeon Richter to collaborate on neuropsychiatric diseases
Biotech | March 11, 2022

AbbVie and Gedeon Richter to collaborate on neuropsychiatric diseases

Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products


Moderna begins Phase 2 study of Omicron-specific bivalent booster
Biotech | March 11, 2022

Moderna begins Phase 2 study of Omicron-specific bivalent booster

Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine


Amity awards Dr Azad Moopen Doctorate for Philanthropy
Sustainability | March 11, 2022

Amity awards Dr Azad Moopen Doctorate for Philanthropy

Over the last 35 years, Dr. Moopen – Founder Chairman and Managing Director of Aster DM Healthcare has played a phenomenal role in strengthening the healthcare delivery system in GCC


Emmes acquires Casimir, its fourth major acquisition
Biotech | March 11, 2022

Emmes acquires Casimir, its fourth major acquisition

Casimir further differentiates Emmes’ industry-leading rare disease research capabilities


AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment
Biotech | March 11, 2022

AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment

Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally


Cancer surgeons gather in Delhi to learn new cancer therapies
Public Health | March 11, 2022

Cancer surgeons gather in Delhi to learn new cancer therapies

Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system


Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals
interviews | March 10, 2022

Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals

As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma


Gujarat Biotech policy offers incentives to attract small and large firms
News | March 10, 2022

Gujarat Biotech policy offers incentives to attract small and large firms

The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers